Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
23.04
+1.11 (5.06%)
At close: Jan 21, 2025, 4:00 PM
23.00
-0.04 (-0.17%)
After-hours: Jan 21, 2025, 5:08 PM EST
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 38.91, with a low estimate of 24 and a high estimate of 87. The average target predicts an increase of 68.88% from the current stock price of 23.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DNLI stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 5 |
| Hold | 1 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 11 | 11 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $28 → $24 | Buy | Maintains | $28 → $24 | +4.17% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $87 | Strong Buy | Maintains | $90 → $87 | +277.60% | Jan 7, 2025 |
| Baird | Baird | Buy Initiates $31 | Buy | Initiates | $31 | +34.55% | Jan 7, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 3, 2025 |
| Stifel | Stifel | Hold → Strong Buy Upgrades $37 | Hold → Strong Buy | Upgrades | $37 | +60.59% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
5.87M
from 330.53M
Decreased by -98.23%
Revenue Next Year
44.06M
from 5.87M
Increased by 651.24%
EPS This Year
-2.85
from -1.06
EPS Next Year
-2.99
from -2.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 23.6M | 164.3M | 567.4M | |||
| Avg | 5.9M | 44.1M | 163.0M | |||
| Low | n/a | n/a | 15.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -92.9% | 2,701.9% | 1,187.8% | |||
| Avg | -98.2% | 651.2% | 269.8% | |||
| Low | - | - | -65.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.69 | -2.17 | -0.72 | |||
| Avg | -2.85 | -2.99 | -2.37 | |||
| Low | -3.08 | -3.43 | -3.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.